Critical Comparison: Longevity Health (XAGE) vs. Its Peers

Valuation & Earnings

This table compares Longevity Health and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Longevity Health	$1.05 million	-$10.37 million	-0.07
Longevity Health Competitors	$59.54 million	-$32.15 million	3.99

Longevity Health’s competitors have higher revenue, but lower earnings than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Longevity Health has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, Longevity Health’s competitors have a beta of 1.76, meaning that their average stock price is 76% more volatile than the S&P 500.

Profitability

This table compares Longevity Health and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Longevity Health Competitors	-672.41%	-133.75%	-59.01%

Institutional & Insider Ownership

24.2% of Longevity Health shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 29.0% of Longevity Health shares are owned by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Longevity Health competitors beat Longevity Health on 5 of the 9 factors compared.

About Longevity Health

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.